Science AI Journal
Medicine · Research topic

Open research questions in Cytomegalovirus and herpesvirus research

495 gap statements mined from Cytomegalovirus and herpesvirus research papers in our 7.9M-paper local library, which holds 1,632 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Cytomegalovirus and herpesvirus research? See the ranked Medicine journals.

What the literature leaves open

  • The optimal management of CMV retinitis in HIV-negative patients with underlying immunosuppressive conditions is not well established. There is limited published evidence on the use of bendamustine-rituximab in patients with MCL and the associated risk of CMV retinitis.

    Case Report: Cytomegalovirus retinitis in an HIV-negative patient with splenic mantle cell lymphoma treated with bendamustine-rituximab · 2026 · DOI

  • Current methods for detecting anti-CMV antibodies have limitations. There is a need for a highly sensitive detection method for acquired immunity to Cytomegalovirus.

    Peptide-Based Plasmon-Enhanced Spectroscopic Immunoassay to Detect Immunity Against Cytomegalovirus · 2025 · DOI

  • Cytomegalovirus (CMV) retinitis following bendamustine-containing therapy is a rare opportunistic infection with limited published evidence, and its optimal management in human immunodeficiency virus (HIV)-negative patients remains poorly defined.

    Case Report: Cytomegalovirus retinitis in an HIV-negative patient with splenic mantle cell lymphoma treated with bendamustine-rituximab · 2026 · DOI

  • Future research is needed to evaluate the long-term effects of interventions by specialty pharmacists on maribavir patient outcomes.

    Optimizing maribavir management: The role of health system specialty pharmacies in access, monitoring, and waste reduction · 2025 · DOI

  • While antiviral therapies for CMV are approved, these compounds are limited by their toxicity and inability to specifically target the latent reservoir or prevent reactivation.

    Inhibition of MAPK signaling suppresses cytomegalovirus reactivation in CD34+ Kasumi-3 cells · 2025 · DOI

  • This case highlights the potential of novel antiviral agents and underscores the need for further research on refractory CMV management.

    Managing refractory cytomegalovirus in an immunosuppressed patient with sarcoidosis: a case report on maribavir therapy · 2025 · DOI

  • Although no standardized diagnostic criteria exist, the lymphocyte and histiocyte infiltration with tissue necrosis in this case suggests CNS involvement in HPS based on the exclusion of other possible diseases (25). These findings are inconsistent with those of the present case.

    Autopsy Case of a Disseminated Cytomegalovirus Infection with a Cutaneous Ulcer Mimicking Rheumatoid Vasculitis · 2026 · DOI

  • The optimal dosing strategy for valganciclovir (VGCV) prophylaxis against cytomegalovirus (CMV) infection in pediatric patients after kidney transplantation (KT) remains uncertain because of the narrow therapeutic window between antiviral efficacy and safety.

    Efficacy and safety of reduced-dose valganciclovir prophylaxis for cytomegalovirus infection after pediatric kidney transplantation · 2026 · DOI

  • While not investigated here, the use of alternative FDA-approved CMV prophylactic agents that are not associated with neutropenia and leukopenia may reduce the burden of disease.

    Short and Long-Term Outcomes in Kidney Transplant Recipients with Neutropenia or Leukopenia Following CMV Prophylaxis · 2026 · DOI

  • Further investigation of vaccine responses in patients with diabetes is needed. Optimized vaccination strategies, including potential booster approaches, should be evaluated in prospective studies. The study's results suggest the need for tailored vaccination strategies for patients with a high Charlson score.

    Immunogenicity of PCV13 during Hospitalization soon after infection resolution: Vaccis study · 2026 · DOI

  • There is a lack of data on pneumococcal vaccine response rates in patients recovering from sepsis. The study aims to address this gap by evaluating the immunogenicity of PCV13 in adult patients hospitalized for infections.

    Immunogenicity of PCV13 during Hospitalization soon after infection resolution: Vaccis study · 2026 · DOI

  • There is no coherent theory of the causal and pathophysiological mechanisms of long COVID. Prior studies have not fully investigated the role of Herpesviridae family viruses in patients with long COVID.

    The role of Herpesviridae family in the development of long COVID · 2026 · DOI

  • Real-world data on letermovir prophylaxis modalities in France are scarce. There is a need to describe the characteristics of patients with letermovir prophylaxis in France.

    Real-world use of letermovir for CMV prevention in allogeneic hematopoietic cell transplantation recipients in France: a national claims database study · 2026 · DOI

  • HCMV reactivations are a significant problem after allogeneic stem cell transplantation. Nonrelapse mortality remains a significant challenge after transplantation. Immune reconstitution is a complex process that is not fully understood.

    Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxis · 2026 · DOI

  • The study is retrospective and may be subject to biases. The sample size is limited to 276 patients. The study only evaluates the effect of Letermovir on polyclonal immune reconstitution and does not assess other outcomes.

    Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxis · 2026 · DOI

  • The relationship between CMV infection and VTE risk in KTRs is not well understood. Previous studies have limitations due to the timing of serologic diagnosis.

    The risk of venous thromboembolism in kidney transplant recipients is enhanced following a cytomegalovirus infection · 2026 · DOI

  • There is a need for studies on the risk of congenital transmission of CMV in Nigeria. The study aims to address the gap in knowledge on the diagnostic implications of cord blood screening for congenital CMV.

    Laboratory-based surveillance on the risk of congenital transmission of cytomegalovirus virus in Lafia, Nigeria · 2026 · DOI

  • Future research should focus on multicenter, prospective trials to further clarify the role of valacyclovir in congenital CMV infection. Such studies are needed to confirm the protective effect of the therapy on MRI outcomes, to better understand the relationship between dosage and treatment duration, and to determine the optimal therapeutic regimen.

    Serial prenatal MRI evaluation of valacyclovir-treated vs untreated fetuses with congenital cytomegalovirus (cCMV) infection · 2026 · DOI

  • The lack of understanding of the mechanisms underlying CMV-HIV co-infections hinders the development of targeted interventions.

    Cytomegalovirus and HIV Co-Infections During Pregnancy and Early Childhood · 2026 · DOI

  • The developments are readily applicable to a range of other diagnostic contexts where peptide-protein interactions and self-assembly-derived PEF sensors can be leveraged.

    Peptide-Based Plasmon-Enhanced Spectroscopic Immunoassay to Detect Immunity Against Cytomegalovirus · 2025 · DOI

  • Introduction In immunocompetent individuals, past CMV infection has been linked to venous thromboembolism (VTE) risk, but evidence remains inconclusive due to timing of serologic diagnosis.

    The risk of venous thromboembolism in kidney transplant recipients is enhanced following a cytomegalovirus infection · 2026 · DOI

  • Although lower than that reported in pre-ART eras and in other regions, CMVR in sub-Saharan Africa is likely underrecognized and underdiagnosed, often presenting at advanced stages of disease21.

    Prevalence and Risk Factors for Cytomegalovirus Retinitis Among People Living with HIV in Sub-Saharan Africa in the Antiretroviral Therapy Era: A Systematic Review and Meta-Analysis · 2026 · DOI

  • The pooled prevalence of approximately 3% indicates that cytomegalovirus retinitis remains a clinically significant and under-recognized opportunistic infection, affecting nearly one in thirty individuals with advanced immunosuppression.

    Prevalence and Risk Factors for Cytomegalovirus Retinitis Among People Living with HIV in Sub-Saharan Africa in the Antiretroviral Therapy Era: A Systematic Review and Meta-Analysis · 2026 · DOI

  • The study identifies a gap in the understanding of the influence of Cytomegalovirus antibodies on immunological markers in Iraqi women with unexplained miscarriage. The study aims to fill this gap by investigating the association of these immunological markers with risk factors for unexplained spontaneous miscarriage.

    Detection of Cytomegalovirus antibodies and immunological markers in cases of unexplained miscarriage: Revealing underlying factors in Iraqi women · 2026 · DOI

  • Another limitation of the present study is that, within the group of treated patients, the fetal MRI examinations were performed using different scanners…

    Serial prenatal MRI evaluation of valacyclovir-treated vs untreated fetuses with congenital cytomegalovirus (cCMV) infection · 2026 · DOI

Most-cited papers in Cytomegalovirus and herpesvirus research

Most recent work

Find a gap in your own Cytomegalovirus and herpesvirus research sub-topic

This page shows what the Cytomegalovirus and herpesvirus research literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,200 open questions
Dementia and Cognitive Impairment Research
2,789 open questions
Substance Abuse Treatment and Outcomes
2,285 open questions
Cancer Immunotherapy and Biomarkers
2,273 open questions
Liver Disease Diagnosis and Treatment
2,102 open questions
Sports Performance and Training
1,952 open questions
Parkinson's Disease Mechanisms and Treatments
1,915 open questions
Mosquito-borne diseases and control
1,849 open questions
Open questions raised by papers listed on this page include: (1) The optimal management of CMV retinitis in HIV-negative patients with underlying immunosuppressive conditions is not well established (“Case Report: Cytomegalovirus retinitis in an HIV-negative patient with splenic…”, 2026); (2) Further investigation of vaccine responses in patients with diabetes is needed (“Immunogenicity of PCV13 during Hospitalization soon after infection resolution:…”, 2026); (3) There is no coherent theory of the causal and pathophysiological mechanisms of long COVID (“The role of Herpesviridae family in the development of long COVID”, 2026); (4) Real-world data on letermovir prophylaxis modalities in France are scarce (“Real-world use of letermovir for CMV prevention in allogeneic hematopoietic…”, 2026); (5) Immune reconstitution is a complex process that is not fully understood (“Letermovir does not affect long-term polyclonal immune reconstitution after…”, 2026). 495 gap statements have been mined from Cytomegalovirus and herpesvirus research papers in our 7.9M-paper local library, which holds 1,632 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.